SHINGRIX PRODUCT INFORMATION SESSION

PRESENTED BY GSK MEDICAL

SHINGRIX is indicated for prevention of herpes zoster (HZ, or shingles) in adults 50 years of age or older.

SHINGRIX
HERPES ZOSTER VACCINE (NON-LIVE RECOMBINANT, AS01$_B$ ADJUVANTED)

You are invited to attend an Information Session about SHINGRIX, the new non-live shingles vaccine coming in January 2018.

Register to participate and learn about what SHINGRIX can do to help protect your patients ≥50 years of age against shingles.

Key learning objectives:

- Drug indication
- Mechanism of action
- How SHINGRIX performed in clinical trials
  - Efficacy data
  - Safety profile
  - Adverse events

SPEAKER: Dr. Heather VanSeggelen
GSK Medical Scientific Advisor, Vaccines

AGENDA: 6:30pm Reception
7:00pm Presentation/Dinner
7:45pm Q&A
8:30pm Close

DATE: Tuesday, May 29, 2018

TIME: 6:30 PM

LOCATION: The Grand Olympia
660 Barton St., Stoney Creek
905-643-4291

FOR MORE INFORMATION OR TO RSVP, PLEASE CONTACT YOUR GSK REPRESENTATIVE AT:

Paul Beesley
paul.d.beesley@gsk.com
cell 905-517-8503

SHINGRIX

HERPES ZOSTER VACCINE (NON-LIVE RECOMBINANT, AS01$_B$ ADJUVANTED)

IMPORTANT SAFETY INFORMATION

Most serious warnings and precautions:

- **Administration:** Do not administer the vaccine intravascularly, intradermally or subcutaneously.

Other relevant warnings and precautions:

- A protective immune response may not be elicited in all vaccinees
- Not for prevention of primary varicella infection or treatment of HZ or postherpetic neuralgia
- Postpone in those with acute severe febrile illness
- Use with caution in those with thrombocytopenia or any coagulation disorder
- Syncope may occur following or before any vaccination as a psychogenic response
- Use in special populations such as pregnant or nursing women or pediatrics (<18 years of age) has not been established
- Limited data in immunocompromised adults 50 years of age or older

Adverse events:

- Solicited local and general adverse reactions that occurred in clinical trails within 7 days of vaccination in subjects aged 50–69 and ≥70 years respectively were: pain (85%, 69.2%), redness (38.5%, 37.7%), swelling at the injection site (28.5%, 23.0%), myalgia (53.0%, 35.1%), fatigue (51.3%, 36.6%), headache (45.2%, 29.0%), shivering (33.1%, 19.5%), fever (25.9%, 14.3%), gastrointestinal symptoms (20.5%, 13.5%)
- Unsolicited adverse reactions that occurred in clinical trials within 30 days of vaccination in ≥1% of subjects and ≥2-fold higher than placebo recipients included chills (3.5%), injection site pruritus (2.2%), and malaise (1.7%)

For more information

Please consult the product monograph at gsk.ca/SHINGRIX/PM for important information relating to dosing and administration, adverse reactions, contraindications and drug interactions which have not been discussed in this piece. To request a product monograph, or to report an adverse event please call 1-800-387-7374.

Learn more about SHINGRIX at **ThinkSHINGRIX.ca**

This promotional presentation is intended for registered Canadian Health Professionals only.

Reference: 1. SHINGRIX Product Monograph. GlaxoSmithKline Inc., October 13, 2017.

02271 11/17

PAAB

MEMBER OF INNOVATIVE MEDICINES CANADA